(HealthDay News) — For men diagnosed with prostate cancer aged older than 70 years, prolonged androgen deprivation therapy is associated with increased risk for diabetes and cardiovascular disease (CVD), especially among those with comorbidities, according to a study published in The Journal of Urology.
Alicia K. Morgans, MD, from Vanderbilt University and Geriatric Research, Education, and Clinical Center in Nashville, Tennessee, and colleagues examined the correlation of androgen deprivation therapy exposure (2 years or less, more than 2 years, or none) with incident diabetes and CVD in men with nonmetastatic prostate cancer.
The cohort included 3,526 eligible participants, 2,985 of whom did not have diabetes and 3,112 of whom did not have CVD.
In men diagnosed with prostate cancer before age 70 years, androgen deprivation therapy was not associated with an elevated risk for diabetes or CVD, the researchers found.
In older men, prolonged androgen deprivation therapy and increasing age at diagnosis correlated with an increased risk for diabetes (at age 76 years: OR=2.1) and CVD (at age 74 years: OR=1.9).
Compared with men without comorbidities, those with comorbidities had greater risk for diabetes (OR=4.3) and CVD (OR=8.1).
“Older men who receive prolonged androgen deprivation therapy should be closely monitored for diabetes and cardiovascular disease,” the researchers wrote.
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.